REDWOOD CITY, Calif., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), today announced the launch of a new website entitled "Hyperkalemia Clinical Insights" (www.hyperkalemiainsights.com), which was developed by the company as an educational resource for healthcare professionals. Hyperkalemia is a serious condition defined as abnormally elevated levels of potassium in the blood, which is prevalent in patients who suffer from chronic kidney disease (CKD), heart failure, hypertension, and/or diabetes.
The website offers healthcare professionals a consolidated source of information by providing the published data and resources on hyperkalemia in one convenient site. Healthcare professionals can explore clinical evidence on issues such as:
- The strong correlation between kidney function and rates of hyperkalemia
- The association between elevated potassium and the risk and severity of clinical consequences
- Recurrence of hyperkalemia in high-risk patients, such as those with chronic kidney disease and heart failure
- The association between commonly used medications, such as RAAS inhibitors, and increased risk of hyperkalemia in patients with CKD and heart failure
The site also offers information on topics such as potassium homeostasis, the pathogenesis of acute and chronic hyperkalemia, and the management of hyperkalemia.
About Relypsa, Inc.
Relypsa, Inc. is a biopharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases.
CONTACT: Sylvia Wheeler V.P. Investor Relations and Corporate Affairs 650-421-9504 IR@relypsa.com